US-based cardiovascular drug developer Celladon has raised $50.6m in their initial public offering selling 6.325 million shares at $8 each.
Celladon develops and manufactures molecular therapies for the treatment of heart failure. Since its founding in 2000 Celladon has raised $124m in venture capital funding.
Celladon is trading on the Nasdaq as CLDN. Barclays acted as the sole book-running manager for the offering.
The $50.6m is made up from $44m raised through an initial offer of 5.5 million shares and an additional $6.6m from the underwriters’ option to purchase 825,000 additional shares of common stock to cover overallotments.
Investors in…
